Updated clinical trial data show that selinexor added to standard therapies can benefit multiple myeloma patients who have failed multiple prior lines of therapy, Karyopharm Therapeutics announced. This data — from the ongoing Phase 1b/2 STOMP (NCT02343042) trial — was presented in three posters at the European Hematology Association (EHA) annual…
The investigational cancer vaccine galinpepimut-S (GPS) has been designated an orphan drug by the U.S. Food and Drug Administration as a possible treatment of multiple myeloma, Sellas Life Sciences announced. The FDA’s orphan drug designation is expected to support and expedite the clinical development and regulatory review…
The supervised use of medicinal cannabis is safe and effective at relieving pain and reducing chemotherapy-induced nausea and vomiting in cancer patients, an increasing body of research data shows. In a new feature issue of the European Journal of Internal Medicine, researchers revised the current data on cannabis and derived products…
A new clinical trial will determine if an exercise program before an autologous stem cell transplant can improve treatment-related side effects in multiple myeloma patients. The trial details are summarized in a report, “Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients…
Seattle Genetics‘ investigational therapy SGN-CD48A, being evaluated in a Phase 1 clinical trial for relapsed or refractory multiple myeloma, was successfully delivered to the trial’s first patient, the company announced. The multicenter open-label trial (NCT03379584) will assess the safety and escalating doses of SGN-CD48A in roughly…
Patients with a condition called monoclonal gammopathy of undetermined significance, characterized by the presence of the abnormal monoclonal or M protein, have a small but persistent risk of multiple myeloma or a related cancer, even after they’d been stable for 30 years, researchers found. The study, “Long-Term…
The U.S. Food and Drug Admnistration will give priority review to Darzalex (daratumumab) as an add-on to standard treatments for multiple myeloma patients who cannot have a stem cell transplant. Janssen Biotech filed the supplemental Biologics License Application for Darzalex to be used in combination with either Velcade (bortezomib), Alkeran (melphalan),…
Gamida Cell is enrolling participants in a Phase 1 clinical trial of an immunotherapy for myeloma and non-Hodgkin’s lymphoma that is based on expanding the number of the body’s natural killer cells to fight the cancers. The study (NCT03019666) will assess the safety and preliminary effectiveness of the treatment in…
The European Commission has granted orphan drug status to CellProtect as a treatment for multiple myeloma, according to the investigational therapy’s developer, CellProtect Nordic Pharmaceuticals. Using patients’ own blood cells, CellProtect is made of a group of immune cells called natural killer (NK) cells that are activated…
The U.S. Food and Drug Administration (FDA) has accepted Ascentage Pharma‘s Investigational New Drug (IND) application for APG-1387, allowing Ascentage to test the anti-cancer drug candidate in clinical trials. APG-1387 is an inhibitor of a class of proteins called inhibitors of apoptosis (IAP) – a type of programmed…
Get regular updates to your inbox.